|
|
Blood, 1 November 2003, Vol. 102, No. 9, pp. 3349-3353.
Prepublished online as a Blood First Edition Paper on July 3, 2003; DOI 10.1182/blood-2003-03-0851.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro
Naoya Ochiai,
Ryo Uchida,
Shin-ichi Fuchida,
Akira Okano,
Masashi Okamoto,
Eishi Ashihara,
Tohru Inaba,
Naohisa Fujita,
Hiroaki Matsubara, and
Chihiro Shimazaki
From the Department of Medicine, Division of Hematology and Oncology; the Division of Cardiology and Vascular Regenerative Medicine; and the Department of Clinical Molecular Genetics and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Ras gene mutations occur in 30% to 40% of patients with multiple myeloma (MM), and farnesylation is the first and most important step in the posttranslational modification of Ras proteins. R115777 is a newly synthesized potent farnesyl transferase inhibitor (FTI) and has recently demonstrated significant antitumor activities in vitro and in vivo. Therefore, we examined the effect of R115777 on the growth of fresh and cloned myeloma cells in vitro. R115777 inhibited the growth of fresh and cloned myeloma cells dose dependently, and effects were not dependent on the status of N-Ras mutation in fresh myeloma cells. Flow cytometric analysis using annexin V and 7-aminoactinomycin D (7AAD) showed that R115777 induced apoptosis of 2 of 3 myeloma cell lines at a concentration of 1.0 x 10-8 M. R115777 appears to be a potent inducer of apoptosis, and its effects depend on the status of Ras mutation in cloned myeloma cells but not on the status of N-Ras mutation in fresh myeloma cells. This is the first report that demonstrates the relationship between the N-Ras mutation in fresh myeloma cells and the effect of R115777. R115777 might have some benefit in the treatment of myeloma patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Qiu, X. Liu, W. Zou, P. Yue, S. Lonial, F. R. Khuri, and S.-Y. Sun
The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells
Cancer Res.,
May 15, 2007;
67(10):
4973 - 4980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Vitale, W. W. de Herder, P. M. van Koetsveld, M. Waaijers, W. Schoordijk, E. Croze, A. Colao, S. W.J. Lamberts, and L. J. Hofland
IFN-{beta} Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro
Cancer Res.,
January 1, 2006;
66(1):
554 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. David, S.-Y. Sun, E. K. Waller, J. Chen, F. R. Khuri, and S. Lonial
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT
Blood,
December 15, 2005;
106(13):
4322 - 4329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Y. Pei, Y. Dai, M. Rahmani, W. Li, P. Dent, and S. Grant
The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells
Clin. Cancer Res.,
June 15, 2005;
11(12):
4589 - 4600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Dasgupta, W. Li, A. Perry, and D. H. Gutmann
Glioma Formation in Neurofibromatosis 1 Reflects Preferential Activation of K-RAS in Astrocytes
Cancer Res.,
January 1, 2005;
65(1):
236 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood,
August 1, 2004;
104(3):
607 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Kropff and J. Kienast
Myeloma: targeted therapies march on
Blood,
May 1, 2004;
103(9):
3247 - 3248.
[Full Text]
[PDF]
|
|
|
|
|
